Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer.

IF 2 4区医学 Q3 ONCOLOGY

Chemotherapy Pub Date : 2025-03-13 DOI:10.1159/000545185

Li Wang, Kai Yang, Xinxin Xie, Hailiang Wei, Pengli Wang, Shaohui Wang

{"title":"Cryoablation Combined with Programmed Cell Death Protein 1 Inhibitor Pembrolizumab for Advanced Non-Small Cell Lung Cancer.","authors":"Li Wang, Kai Yang, Xinxin Xie, Hailiang Wei, Pengli Wang, Shaohui Wang","doi":"10.1159/000545185","DOIUrl":null,"url":null,"abstract":"Introduction: This study aims to evaluate the efficacy and safety of cryoablation combined with pembrolizumab treatment versus cryoablation alone in patients with advanced non-small cell lung cancer (NSCLC).Methods: This retrospective study was conducted from February 2018 to October 2021. A total of 90 patients with NSCLC (AJCC stage IIIB/IV) were included, with 36 patients receiving cryoablation combined with pembrolizumab (group A) and 54 patients receiving cryoablation alone (group B). The primary outcome measures included objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), immune responses, and adverse events serving as secondary endpoints. Risk factors for OS and PFS were identified using univariate and multivariate analyses.Results: No treatment-related deaths were observed. Group A demonstrated a higher ORR (75.0% vs. 61.1%), longer median OS (28.1 months vs. 24.2 months), and longer median PFS (12.8 months vs. 8.4 months) compared to Group B. Additionally, group A showed significant increases in CD3+, CD4+, and CD8+ T cells, and elevated levels of interleukin-2, interleukin-6, TNF-β, and interferon-γ. The multivariate analysis showed the combination of cryoablation and pembrolizumab was an independent prognostic factor for OS and PFS.Conclusions: Cryoablation combined with pembrolizumab significantly improves clinical outcomes in advanced NSCLC patients compared to cryoablation alone, highlighting the potential of this combination therapy in enhancing antitumor immunity and prolonging survival.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545185","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study aims to evaluate the efficacy and safety of cryoablation combined with pembrolizumab treatment versus cryoablation alone in patients with advanced non-small cell lung cancer (NSCLC).

Methods: This retrospective study was conducted from February 2018 to October 2021. A total of 90 patients with NSCLC (AJCC stage IIIB/IV) were included, with 36 patients receiving cryoablation combined with pembrolizumab (group A) and 54 patients receiving cryoablation alone (group B). The primary outcome measures included objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), immune responses, and adverse events serving as secondary endpoints. Risk factors for OS and PFS were identified using univariate and multivariate analyses.

Results: No treatment-related deaths were observed. Group A demonstrated a higher ORR (75.0% vs. 61.1%), longer median OS (28.1 months vs. 24.2 months), and longer median PFS (12.8 months vs. 8.4 months) compared to Group B. Additionally, group A showed significant increases in CD3+, CD4+, and CD8+ T cells, and elevated levels of interleukin-2, interleukin-6, TNF-β, and interferon-γ. The multivariate analysis showed the combination of cryoablation and pembrolizumab was an independent prognostic factor for OS and PFS.

Conclusions: Cryoablation combined with pembrolizumab significantly improves clinical outcomes in advanced NSCLC patients compared to cryoablation alone, highlighting the potential of this combination therapy in enhancing antitumor immunity and prolonging survival.

查看原文本刊更多论文

冷冻消融联合程序性细胞死亡蛋白1抑制剂派姆单抗治疗晚期非小细胞肺癌

目的：评价冷冻消融联合派姆单抗治疗与单独冷冻消融治疗晚期非小细胞肺癌（NSCLC）患者的疗效和安全性。方法：回顾性研究于2018年2月至2021年10月进行。共纳入90例NSCLC （AJCC IIIB/IV期）患者，其中36例患者接受冷冻消融联合派embrolizumab （A组），54例患者接受单独冷冻消融（B组）。主要结局指标包括客观缓解率（ORR）、总生存期（OS）和无进展生存期（PFS），免疫反应和不良事件作为次要终点。采用单因素和多因素分析确定OS和PFS的危险因素。结果：未观察到治疗相关死亡。与b组相比，A组表现出更高的ORR (75.0% vs. 61.1%)，更长的中位OS（28.1个月vs. 24.2个月）和更长的中位PFS（12.8个月vs. 8.4个月）。此外，A组显示CD3+， CD4+和CD8+ T细胞显著增加，IL-2, IL-6， TNF-β和IFN-γ水平升高。多因素分析显示，冷冻消融联合派姆单抗是OS和PFS的独立预后因素。结论：与单独冷冻消融相比，冷冻消融联合派姆单抗显著改善了晚期NSCLC患者的临床结果，突出了这种联合治疗在增强抗肿瘤免疫和延长生存期方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemotherapy 医学-药学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.